Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beigene Ltd ADR
(NQ:
BGNE
)
204.02
+5.43 (+2.73%)
Streaming Delayed Price
Updated: 11:45 AM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia
January 20, 2022
From
BeiGene
Via
Business Wire
BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference
January 06, 2022
From
BeiGene, Ltd.
Via
Business Wire
China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
January 06, 2022
From
BeiGene
Via
Business Wire
BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene’s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets
December 20, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
December 14, 2021
From
BeiGene, Ltd.
Via
Business Wire
Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of China
December 13, 2021
From
BeiGene
Via
Business Wire
BeiGene Presents Results from SEQUOIA Trial of BRUKINSA (zanubrutinib) in First-Line Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting
December 12, 2021
From
BeiGene
Via
Business Wire
BeiGene Presents Updated Safety and Efficacy Findings on BRUKINSA (zanubrutinib) in BTK Inhibitor-Intolerant Patients with Relapsed or Refractory B-Cell Malignancies
December 11, 2021
From
BeiGene
Via
Business Wire
BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021
December 10, 2021
From
BeiGene
Via
Business Wire
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
December 02, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in Three New Indications, BRUKINSA® (Zanubrutinib) in One New Indication, and the First Listing for Pamiparib
December 02, 2021
From
BeiGene
Via
Business Wire
BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021
December 02, 2021
From
BeiGene
Via
Business Wire
BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
November 30, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström’s Macroglobulinemia
November 23, 2021
From
BeiGene
Via
Business Wire
BeiGene Launches Proposed Initial Public Offering on the STAR Market in China
November 23, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Closes on Property for New U.S. Manufacturing and Clinical R&D Center
November 23, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339
November 22, 2021
From
BeiGene
Via
Business Wire
BeiGene and NewBridge Pharmaceuticals Announce Approval in Saudi Arabia of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
November 14, 2021
From
BeiGene
Via
Business Wire
BeiGene Reports Third Quarter 2021 Financial Results
November 04, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting
November 04, 2021
From
BeiGene
Via
Business Wire
BeiGene and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
October 20, 2021
From
BeiGene
Via
Business Wire
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia
October 10, 2021
From
BeiGene
Via
Business Wire
BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström’s Macroglobulinemia
October 07, 2021
From
BeiGene
Via
Business Wire
BeiGene Announces Inclusion in FTSE Russell Indices
September 20, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia
September 17, 2021
From
BeiGene
Via
Business Wire
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
September 15, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma
September 13, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021
September 12, 2021
From
BeiGene, Ltd.
Via
Business Wire
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia
September 01, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer
August 22, 2021
From
BeiGene, Ltd.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.